Investors

ViaCyte is a privately-funded regenerative medicine company focused on cell replacement therapies for unmet medical needs. Our investors are major supporters and experienced partners in the life science sectors. Working with them, we believe we can realize the promise of ViaCyte’s break-through technologies for the benefit of patients and investors alike.

BainCapital - Life Sciences

Bain Capital

Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with approximately $105 billion of assets under management that creates lasting impact for investors, teams, businesses, and communities. Bain Capital Life Sciences invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies globally, with a focus on companies that both drive medical innovation across the value chain and enable that innovation to improve the lives of patients with unmet medical needs. The differentiated skillset of Bain Capital’s team enables it to pursue opportunities created by several long-term trends in healthcare. In particular, these trends are creating an increased need for targeted capital and value-added strategic support of companies around their critical phases of growth, during which they must prove their clinical and business value.

Visit Website

Asset Management Company

For over 45 years, the goal of Asset Management Company has been to partner with visionary entrepreneurs and to help create valuable new companies and important new industries by investing capital in exciting, new, technology-based opportunities. “We have observed the ups and downs of venture capital and the fads and failures in the Valley. So we always took the long view,” says Pitch Johnson, founding partner. As of 2012, Asset Management Company has become a family office. Our focus now is managing the Johnson family investments and supporting a variety of not-for-profit organizations through corporate philanthropy and a family foundation.

Visit Website
Johnson+Johnson Innovation

Johnson & Johnson Innovation

Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson. JJDC pursues opportunities to solve critical healthcare needs. JJDC portfolio companies benefit from the full global capabilities of Johnson & Johnson to collaborate and drive innovation. JJDC invests across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from seed-level startups to Series B and beyond. The JJDC team includes leaders in the healthcare and technology communities, many with deep R&D experience.

Visit Website
RA Capital

RA Capital Management

RA Capital Management® (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital® to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization.

Visit Website
Sanderling Ventures

Sanderling Ventures

Founded in 1979, Sanderling Ventures is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs. Biomedical investing has been a viable sector in the technology markets for more than thirty years, and in the past ten years has experienced accelerated growth. Since its inception, Sanderling has supported more than 90 biomedical companies from very early stage start-ups, through commercial development, earning consistently high rates of return on its venture investments.

Visit Website
TPG

TPG

TPG is a leading global alternative asset firm founded in 1992 with more than $104 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio.

Visit Website

Sign up for updates

To have our press releases and major updates sent to you, please provide your name and email address.